The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Summer 2025 RFA: Personalized Approaches for Understanding, Assessing and Improving Gait in Parkinson’s Disease Research Program, 2026Precision Mapping of Somato-Cognitive Action Network (SCAN) Pathophysiology in Parkinson’s Disease Gait Disturbance
Study Rationale:
Parkinson’s Disease (PD) is a neurodegenerative disorder caused by dysfunction in specific brain systems. We recently discovered a new brain system called the Somato-Cognitive...
-
Fall 2021 RFA: Promoting Diversity, Equity and Inclusion in Parkinson’s Disease Research, 2022Disparities in Neurocognitive Impairment Among Hispanics and Latinos in the United States with Parkinson’s Disease: The Role of Cardiovascular Risk
Study Rationale: In the United States, Latinos with Parkinson’s disease (PD) are more likely to have problems with memory, planning and other thinking skills than individuals of other ethnic/racial...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Assessing the Aggregation of Alpha-synuclein Across Aging, Alzheimer’s Disease and Dementia with Lewy Bodies
Study Rationale: Forms of alpha-synuclein, the protein that aggregates in Parkinson’s disease (PD), can be detected in cerebrospinal fluid (CSF) by seed amplification assays (SAA). These highly...
-
Research Grant, 2025The BioFINDER Studies: Identifying Disease Stages and Effects of Co-morbidities in Neuronal Synuclein Disease
Study Rationale: Neuronal synuclein disease (NSD) is the underlying cause of Parkinson’s disease (PD) and similar disorders. Recently, new tests have allowed us to measure signs of NSD before symptoms...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Use of an Angiotensin-(1-7) Glycopeptide, to Treat Dementia in Parkinson's Disease
Study Rationale: Peptide-based drugs are attractive candidates for treating the cognitive decline associated with Parkinson’s disease (PD) because they demonstrate a robust safety profile and an...
-
MJFF Research Grant, 2008The anatomic basis of cardiac and cognitive changes in Parkinson's disease: A collaborative study with the Parkinson's Institute, Sunnyvale, CA (USA)
Objective/Rationale:
The heart, particularly the conduction system, is influenced by the parasympathetic and sympathetic nervous systems. Recently, early-occurring Parkinson’s disease-related Lewy...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.